Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate)
## Overview
Hepamerz is a combination of the amino acids L-ornithine and L-aspartate. It is thought to work by promoting the detoxification of ammonia in the liver and brain.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
## Adult Dosing
* **Hepatic Encephalopathy:** Typically administered as an intravenous infusion.
* **Initial Dose:** 5 grams (g) intravenously over 30 minutes.
* **Subsequent Doses:** 5 g to 10 g intravenously every 8 to 12 hours.
* **Maximum Daily Dose:** 30 g intravenously.
* **Oral Administration:** If available and appropriate, may be given orally. Dosing is highly variable and depends on the formulation. Consult specific product information.
## Pediatric Dosing
* Limited data available for pediatric use. Dosing is not well-established and should be determined by a specialist based on individual patient factors and available formulations.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment due to the drug's metabolism and excretion. However, caution is advised in patients with severe hepatic dysfunction.
## Contraindications
* Hypersensitivity to L-ornithine, L-aspartate, or any component of the formulation.
* Severe kidney disease.
* Certain rare metabolic disorders (e.g., urea cycle disorders) due to potential for increased ammonia levels.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal pain, diarrhea, rash, itching.
* **Less Common:** Dizziness, headache, fatigue, muscle pain, flushing.
* **Rare:** Allergic reactions.
## Key Drug Interactions
* **Barbiturates:** May potentially reduce the efficacy of Hepamerz.
* **Sulfonamides:** Potential for interaction, though clinical significance is unclear.
## Monitoring
* Clinical assessment of hepatic encephalopathy symptoms (e.g., confusion, asterixis).
* Electrolytes, renal function, and liver function tests as clinically indicated.
* Ammonia levels may be monitored but do not always correlate directly with clinical response.
## Clinical Pearls
* Hepamerz is primarily used as an adjunct therapy for hepatic encephalopathy.
* It should be administered slowly as an intravenous infusion to minimize adverse effects.
* Oral formulations, if used, have different absorption characteristics and may require higher doses.
* The effectiveness of Hepamerz can be influenced by factors such as the severity of liver disease and the presence of precipitating factors for HE.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and indications may vary by local protocol and specific product availability.
